The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non ‐small cell lung cancer: A meta‐analysis

ConclusionsPersistence of the T790M gene mutation after the development of Osimertinib resistance is associated with higher therapeutic benefits of Osimertinib in NSCLC patients. The results of tissue detection are more significant than those of plasma detection.

Source: The Clinical Respiratory Journal - April 8, 2024 Category: Respiratory Medicine Authors: Liuxian Guo, Guojin Zhou, Min Huang, Kejing Tang, Jing Xu, Jie Chen Tags: REVIEW ARTICLE Source Type: research